Study Casts Doubt on Connection Between DAAs and Liver Cancer Risk

Study Casts Doubt on Connection Between DAAs and Liver Cancer Risk
OCTOBER 15, 2018

Jared Kaltwasser

“There are no significant differences between DAA regimens in HCC risk after antiviral treatment,” concluded the authors, led by Elijah J. Mun, MD, of the University of Washington.

The finding is significant because it suggests that hepatocellular carcinoma risk does not need to be a determining factor in which DAA a physician prescribes. However, the authors say the takeaway from the study can extend even beyond the question of whether any particular DAA therapy is worse than another when it comes to cancer risk. They argue their study suggests DAAs broadly don’t increase the risk of hepatocellular carcinoma

Read the article: https://www.mdmag.com/medical-news/study-casts-doubt-on-connection-between-daas-and-liver-cancer-risk

On This Blog

Sift through current Liver Cancer and Hepatitis C research articles. 

Liver Cancer After Treatment For Hepatitis C:
Research demonstrates that while SVR markedly reduced liver-related complications and liver cancer, some long-term risk for liver cancer remained in those who were cured of Hepatitis C. But after direct-acting antiviral therapy does the risk of developing liver cancer increase? Research is saying no, check out an index of articles here.....